1. Home
  2. CTKB vs SEPN Comparison

CTKB vs SEPN Comparison

Compare CTKB & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTKB
  • SEPN
  • Stock Information
  • Founded
  • CTKB 1990
  • SEPN 2022
  • Country
  • CTKB United States
  • SEPN United States
  • Employees
  • CTKB N/A
  • SEPN N/A
  • Industry
  • CTKB Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • SEPN
  • Sector
  • CTKB Health Care
  • SEPN
  • Exchange
  • CTKB Nasdaq
  • SEPN NYSE
  • Market Cap
  • CTKB 879.8M
  • SEPN 1.0B
  • IPO Year
  • CTKB 2021
  • SEPN 2024
  • Fundamental
  • Price
  • CTKB $5.88
  • SEPN $18.70
  • Analyst Decision
  • CTKB Strong Buy
  • SEPN Strong Buy
  • Analyst Count
  • CTKB 2
  • SEPN 4
  • Target Price
  • CTKB $9.25
  • SEPN $43.67
  • AVG Volume (30 Days)
  • CTKB 758.4K
  • SEPN 418.6K
  • Earning Date
  • CTKB 02-26-2025
  • SEPN 02-15-2025
  • Dividend Yield
  • CTKB N/A
  • SEPN N/A
  • EPS Growth
  • CTKB N/A
  • SEPN N/A
  • EPS
  • CTKB N/A
  • SEPN N/A
  • Revenue
  • CTKB $201,210,000.00
  • SEPN $981,000.00
  • Revenue This Year
  • CTKB $8.18
  • SEPN $406.62
  • Revenue Next Year
  • CTKB $11.15
  • SEPN N/A
  • P/E Ratio
  • CTKB N/A
  • SEPN N/A
  • Revenue Growth
  • CTKB 9.88
  • SEPN N/A
  • 52 Week Low
  • CTKB $4.66
  • SEPN $15.86
  • 52 Week High
  • CTKB $9.33
  • SEPN $28.99
  • Technical
  • Relative Strength Index (RSI)
  • CTKB 41.85
  • SEPN N/A
  • Support Level
  • CTKB $5.37
  • SEPN N/A
  • Resistance Level
  • CTKB $7.30
  • SEPN N/A
  • Average True Range (ATR)
  • CTKB 0.40
  • SEPN 0.00
  • MACD
  • CTKB -0.14
  • SEPN 0.00
  • Stochastic Oscillator
  • CTKB 26.42
  • SEPN 0.00

About CTKB Cytek Biosciences Inc.

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

About SEPN SEPTERNA INC

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, and GLP-1R, GIPR, GCGR.

Share on Social Networks: